AMLX Insider Trading Activity and SEC Form 4 Filings
AMLX insider trading summary
Over the past 12 months, insiders at Amylyx Pharmaceuticals, Inc. (AMLX) reported 29 sales worth $9.6M by 6 insiders and 2 open-market purchases worth $152K by 1 insider on SEC Form 4. Net insider selling was $9.4M.
Latest AMLX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 5, 2026 | George M Milne Jr | Insider | Sell | $831K (30,000 @ $27.70) |
| Sep 10, 2026 | Justin B. Klee | Co-Chief Executive Officer | Sell | $48K (1,439 @ $33.16) |
| Sep 10, 2026 | Camille L Bedrosian | Chief Medical Officer | Sell | $256K (7,947 @ $32.21) |
| Sep 10, 2026 | Justin B. Klee | Co-Chief Executive Officer | Sell | $933K (29,025 @ $32.13) |
| Sep 10, 2026 | Camille L Bedrosian | Chief Medical Officer | Sell | $69K (2,081 @ $33.09) |
| Sep 10, 2026 | James M Frates | Chief Financial Officer | Sell | $315K (9,768 @ $32.27) |
| Sep 10, 2026 | Gina Mazzariello | Chief Legal Officer | Sell | $309K (9,525 @ $32.46) |
| Sep 10, 2026 | James M Frates | Chief Financial Officer | Sell | $35K (1,042 @ $33.23) |
| Sep 10, 2026 | Gina Mazzariello | Chief Legal Officer | Sell | $367 (11 @ $33.34) |
| Sep 10, 2026 | Joshua B Cohen | Co-Chief Executive Officer | Sell | $950K (29,545 @ $32.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.